v3.26.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 3,655 $ 3,556
Accounts receivables, net of allowance for credit losses of $75 million and $81 million as of June 30, 2026 and December 31, 2025, respectively 3,493 3,709
Inventories 3,221 3,179
Prepaid expenses 1,034 1,122
Other current assets 563 539
Assets held for sale 1,794 1,842
Total current assets 13,760 13,946
Deferred income taxes 2,162 2,191
Other non-current assets 387 405
Property, plant and equipment, net 3,928 4,080
Operating lease right-of-use assets, net 333 345
Identifiable intangible assets, net 3,447 3,781
Goodwill 15,839 [1] 16,000
Total assets 39,857 40,748
Current liabilities:    
Short-term debt 4,500 1,820
Sales reserves and allowances 3,899 4,143
Accounts payables 2,721 2,531
Employee-related obligations 488 739
Accrued expenses 2,738 2,687
Other current liabilities 987 1,182
Liabilities held for sale 313 354
Total current liabilities 15,646 13,456
Long-term liabilities:    
Deferred income taxes 289 296
Other taxes and long-term liabilities 3,791 3,808
Senior notes and loans 12,092 14,986
Operating lease liabilities 282 288
Total long-term liabilities 16,454 19,379
Total liabilities 32,100 32,834
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; June 30, 2026 and December 31, 2025: authorized 2,495 million shares; issued 1,271 million shares and 1,257 million shares, respectively. 59 58
Additional paid-in capital 28,256 28,133
Accumulated deficit (13,969) (13,762)
Accumulated other comprehensive loss (2,465) (2,391)
Treasury shares as of June 30, 2026 and December 31, 2025: 106 million ordinary shares and 107 million ordinary shares, respectively (4,128) (4,128)
Stockholders' equity attributable to Teva shareholders 7,753 7,910
Non-controlling interests 4 4
Total equity 7,757 7,914
Total liabilities and equity $ 39,857 $ 40,748
[1] Cumulative goodwill impairment as of June 30, 2026 and December 31, 2025, was approximately $29.6 billion in both periods.